Deinove SA

Many public biopharmaceutical companies have turned to alternatives other than follow-on public offerings (FOPOs) this year to fund their research and development programs while stock prices have been

While the fight against antimicrobial resistance often produces more lamentation than new products, some long-stalled therapies for the notoriously challenging bacteria Clostridium difficile have re

FDA's push to define a regulatory pathway that will encourage development of drugs for single pathogens could be good news for the handful of companies betting on the approach. The agency is consideri

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in